We are always looking for the best external innovation available to complement and extend our in-house capabilities and portfolio.

In addition to our wholly-owned and first-in-class PKMYT1 inhibitor (RP-6306) currently in the clinic, we expect to advance our Polθ inhibitor program (partnered with Ono Pharmaceutical Co. in Japan and selected Asian territories excluding China) into IND-enabling studies in the first half of 2022, and we are developing additional earlier-stage programs generated from, and developed using, our proprietary SNIPRx/STEP² platform. We are always on the look out for great partners to help us enhance our platform and portfolio.

If you are interested in partnering with us, please let us know by filling out our contact form.